(Total Views: 650)
Posted On: 05/31/2025 6:43:24 AM
Post# of 154118
Debu Tripathy is the new Scientific Advisory Board member.
Not to underline the obvious, but he is the Chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, where we started (but apparently did not finish) a study testing Leron w Keytruda in a breast cancer xenograft model. The study was undertaken to evaluate synergistic effects of Leronlimab and Keytruda.
Obviously using Leron + a checkpoint inhibitor vs. breast cancer is a very current topic for CYDY right now.
Whatever happened at Anderson, I don't think it could have shown a failure of the combination, or Dr. Tripathy would not be with us now.
Not to underline the obvious, but he is the Chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, where we started (but apparently did not finish) a study testing Leron w Keytruda in a breast cancer xenograft model. The study was undertaken to evaluate synergistic effects of Leronlimab and Keytruda.
Obviously using Leron + a checkpoint inhibitor vs. breast cancer is a very current topic for CYDY right now.
Whatever happened at Anderson, I don't think it could have shown a failure of the combination, or Dr. Tripathy would not be with us now.
(25)
(0)
